Ask AI
ProCE Banner Activity

H3 K27M–Mutated Diffuse Midline Glioma: Bridging Molecular Pathology and Clinical Care

Podcast

In this podcast, experts discuss the evolving molecular classification, diagnosis, and management of H3 K27M–altered diffuse midline glioma (DMG), emphasizing the clinical implications of histone mutations, epigenetic dysregulation, and tumor location. The discussion explores the limitations of neuroimaging, challenges associated with obtaining tissue from anatomically sensitive regions, and the importance of integrating histopathology with molecular testing to distinguish DMG from other gliomas and diagnostic mimics. Experts also examine emerging diagnostic approaches, including cerebrospinal fluid analysis, cell-free DNA testing, and epigenomic profiling, as well as current and investigational treatment strategies involving radiotherapy, dordaviprone, and CAR T-cell therapies. Additional considerations include the role of tissue stewardship, multidisciplinary collaboration, and postmortem analyses in improving diagnostic accuracy, evaluating therapeutic response, and informing personalized treatment decisions.

Released: November 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the National Brain Tumor Society (NBTS).

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals.

Jazz Pharmaceuticals

Partners

National Brain Tumor Society (NBTS)

ProCE Banner

Target Audience

This activity is intended for pathologists, neuro-oncologists, pediatric neuro-oncologists, and other healthcare professionals who care for patients with diffuse midline glioma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate H3 K27M-mutant tumors from the broader WHO entity diffuse midline glioma, H3 K27-altered, and relevant diagnostic mimics using current WHO classification and CAP and NCCN guidance

  • Develop multidisciplinary biopsy, tissue-stewardship, and reflex-testing workflows that appropriately integrate H3 K27M and H3K27me3 IHC, NGS, and DNA methylation profiling

  • Interpret concordant, discordant, and limited molecular findings and construct an integrated pathology report that communicates the exact alteration, diagnosis, assay limitations, and clinical relevance

  • Translate confirmed H3 K27M results into timely multidisciplinary treatment planning, approved-therapy eligibility assessment, prognostic counseling, and clinical trial referral

Financial Disclosures

Primary Author

Craig Horbinski, MD, PhD, has no relevant financial relationships to disclose.

Michael W. Ruff, MD: consultant/advisor/speaker: Curio, Radmetrix, Servier.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and generating transcripts from audio/video files. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.